Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU

被引:44
|
作者
Tamura, M
Ajayi, T
Allmond, LR
Moriyama, K
Wiener-Kronish, JP
Sawa, T [1 ]
机构
[1] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA
关键词
Pseudomonas aeruginosa; type III secretion system; ExoU; phospholipase A; lysophospholipase A; acute lung injury; cytotoxin;
D O I
10.1016/j.bbrc.2004.02.050
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acute lung injury in Pseudomonas aeruginosa pneumonia depends primarily on ExoU that is delivered directly into the eukaryotic cell via the type III secretion system. Recent studies demonstrated that ExoU has lipase activity, and that the cytotoxicity of ExoU is dependent on its patatin-like phospholipase domain. We investigated the phospholipase A (PLA) activity of ExoU. ExoU, but not non-catalytic ExoU-S142A, preincubated with the BEAS-2B cell lysate showed a weak increase of Ca2+-independent PLA(2) activity. When activated ExoU was mixed with secretory type PLA2, more phospholipase activity was observed, suggesting that ExoU has lysophospholipase A (lysoPLA) activity. A significant increase in lysoPLA activity was also observed. Glycerol enhanced this activity and inhibitors of iPLA, suppressed ExoUs lysoPLA activity. Our results suggest that ExoU has a potent lysoPLA activity that requires the presence of the catalytically active site Ser(142) with an unknown eukaryotic cell factor(s) for its activation. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:323 / 331
页数:9
相关论文
共 50 条
  • [21] Perspectives on the Pseudomonas aeruginosa Type III Secretion System Effector ExoU and Its Subversion of the Host Innate Immune Response to Infection
    Hardy, Kierra S.
    Tessmer, Maxx H.
    Frank, Dara W.
    Audia, Jonathon P.
    TOXINS, 2021, 13 (12)
  • [22] PSEUDOMONAS AERUGINOSA EXOU AUGMENTS NEUTROPHIL TRANSEPITHELIAL MIGRATION
    Lanter, B. B.
    Pazos, M. A.
    Yonker, L.
    Hurley, B. P.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 345 - 346
  • [23] Implications of oxidative stress in the cytotoxicity of Pseudomonas aeruginosa ExoU
    Saliba, AM
    de Assis, MC
    Nishi, R
    Raymond, B
    Marques, ED
    Lopes, UG
    Touqui, L
    Plotkowski, MC
    MICROBES AND INFECTION, 2006, 8 (02) : 450 - 459
  • [24] Type III secretory products of Pseudomonas aeruginosa upregulate interleukin-10 in macrophages.
    Haight, M
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 75A - 75A
  • [25] O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa
    Faure, K
    Shimabukuro, D
    Ajayi, T
    Allmond, LR
    Sawa, T
    Wiener-Kronish, JP
    JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (05) : 2158 - 2160
  • [26] ExoU-induced procoagulant activity in Pseudomonas aeruginosa-infected airway cells
    Plotkowski, M. C.
    Feliciano, L. F. P.
    Machado, G. B. S.
    Cunha, L. G., Jr.
    Freitas, C.
    Saliba, A. M.
    de Assis, M. C.
    EUROPEAN RESPIRATORY JOURNAL, 2008, 32 (06) : 1591 - 1598
  • [27] Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU
    Lee, Vincent T.
    Pukatzki, Stefan
    Sato, Hiromi
    Kikawada, Eriya
    Kazimirova, Anastasia A.
    Huang, Jin
    Li, Xiaohua
    Arm, Jonathan P.
    Frank, Dara W.
    Lory, Stephen
    INFECTION AND IMMUNITY, 2007, 75 (03) : 1089 - 1098
  • [28] Association between possession of ExoU and antibiotic resistance in Pseudomonas aeruginosa
    Subedi, Dinesh
    Vijay, Ajay Kumar
    Kohli, Gurjeet Singh
    Rice, Scott A.
    Willcox, Mark
    PLOS ONE, 2018, 13 (09):
  • [29] Investigating Structural Properties of Pseudomonas Aeruginosa Exou Toxin Upon Interaction with Liposome and Nanodisc Bilayers by EPR Spectroscopy
    Springer, Tzvia I.
    Kohn, Samantha
    Feix, Jimmy
    BIOPHYSICAL JOURNAL, 2018, 114 (03) : 614A - 614A
  • [30] Novel Type III Effectors in Pseudomonas aeruginosa
    Burstein, David
    Satanower, Shirley
    Simovitch, Michal
    Belnik, Yana
    Zehavi, Meital
    Yerushalmi, Gal
    Ben-Aroya, Shay
    Pupko, Tal
    Banin, Ehud
    MBIO, 2015, 6 (02):